Lundbeck Q3 2019 Financial Results

Brintellix/Trintellix continues its significant growth momentum +33% 2.400 * Grew 31% (28% in L.C.) to DKK I 2,023 million in 9M 2019 Brintellix/Trintellix sales (Quarterly DKKm) Continued solid traction in 1800 North America volume share gains Int. Markets *>2.5%: Finland, France, Italy, Europe 600 Norway, South Korea, Spain, Switzerland * In the U.S., volume is up 22% y/y in Q3 20191) 400 Trintellix approved in Japan in September 1) Symphony Health (cf. Bloomberg) 6 200 2.000 Brintellix/Trintellix sales (9M - DKKm) 1.600 1.200 800 400 T +31% 0 Q3.17 Q3.18 Q3.19 9M.17 9M.18 9M.19 Lundbeck

View entire presentation